- Home
- ALLO vs TNGX Comparison
ALLO vs TNGX Comparison
Compare ALLO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- TNGX
- Stock Information
- Founded
- ALLO 2017
- TNGX 2014
- Country
- ALLO United States
- TNGX United States
- Employees
- ALLO N/A
- TNGX N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ALLO Health Care
- TNGX Health Care
- Exchange
- ALLO Nasdaq
- TNGX Nasdaq
- Market Cap
- ALLO 338.9M
- TNGX 317.4M
- IPO Year
- ALLO 2018
- TNGX N/A
- Fundamental
- Price
- ALLO $1.55
- TNGX $1.46
- Analyst Decision
- ALLO Strong Buy
- TNGX Strong Buy
- Analyst Count
- ALLO 10
- TNGX 7
- Target Price
- ALLO $9.66
- TNGX $12.33
- AVG Volume (30 Days)
- ALLO 2.6M
- TNGX 638.9K
- Earning Date
- ALLO 05-12-2025
- TNGX 05-07-2025
- Dividend Yield
- ALLO N/A
- TNGX N/A
- EPS Growth
- ALLO N/A
- TNGX N/A
- EPS
- ALLO N/A
- TNGX N/A
- Revenue
- ALLO $22,000.00
- TNGX $42,069,000.00
- Revenue This Year
- ALLO N/A
- TNGX N/A
- Revenue Next Year
- ALLO $9.07
- TNGX N/A
- P/E Ratio
- ALLO N/A
- TNGX N/A
- Revenue Growth
- ALLO N/A
- TNGX 15.17
- 52 Week Low
- ALLO $1.23
- TNGX $1.11
- 52 Week High
- ALLO $3.78
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- ALLO 49.84
- TNGX 46.79
- Support Level
- ALLO $1.38
- TNGX $1.24
- Resistance Level
- ALLO $1.75
- TNGX $1.65
- Average True Range (ATR)
- ALLO 0.13
- TNGX 0.16
- MACD
- ALLO 0.04
- TNGX 0.05
- Stochastic Oscillator
- ALLO 61.54
- TNGX 64.81
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.